Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Investing Activities (2016 - 2025)

Altimmune (ALT) has disclosed Cash from Investing Activities for 16 consecutive years, with -$149.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 12553.79% to -$149.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$39.7 million, a 20.6% increase, with the full-year FY2024 number at -$28.4 million, down 306.71% from a year prior.
  • Cash from Investing Activities was -$149.3 million for Q3 2025 at Altimmune, down from $101.1 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $101.1 million in Q2 2025 to a low of -$149.3 million in Q3 2025.
  • A 5-year average of -$2.8 million and a median of $1.2 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 147900.0% in 2023, then plummeted 12553.79% in 2025.
  • Altimmune's Cash from Investing Activities stood at $24.9 million in 2021, then crashed by 96.06% to $981000.0 in 2022, then plummeted by 911.31% to -$8.0 million in 2023, then surged by 271.28% to $13.6 million in 2024, then crashed by 1195.37% to -$149.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Cash from Investing Activities are -$149.3 million (Q3 2025), $101.1 million (Q2 2025), and -$5.1 million (Q1 2025).